385 related articles for article (PubMed ID: 25772923)
1. Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
Nabi MG; Ahangar A; Wahid MA; Kuchay S
Niger J Clin Pract; 2015; 18(3):381-6. PubMed ID: 25772923
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
4. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.
Sharma M; Sharma JD; Sarma A; Ahmed S; Kataki AC; Saxena R; Sharma D
Asian Pac J Cancer Prev; 2014; 15(11):4507-11. PubMed ID: 24969877
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic characteristic features of triple negative and nontriple negative breast cancer at a tertiary care hospital.
Mohapatra M
J Cancer Res Ther; 2023; 19(5):1186-1193. PubMed ID: 37787282
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
[TBL] [Abstract][Full Text] [Related]
10. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA
Breast J; 2015; 21(6):627-33. PubMed ID: 26547900
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
Zhu X; Ying J; Wang F; Wang J; Yang H
Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
[TBL] [Abstract][Full Text] [Related]
13. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
14. An institutional analysis of clinicopathological features of triple negative breast cancer.
Sharma D; Singh G
Indian J Cancer; 2016; 53(4):566-568. PubMed ID: 28485352
[TBL] [Abstract][Full Text] [Related]
15. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
17. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
[TBL] [Abstract][Full Text] [Related]
18. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
19. Age-related frequency of triple negative breast cancer in women.
Sajid MT; Ahmed M; Azhar M; Mustafa QU; Shukr I; Ahmed M; Kamal Z
J Coll Physicians Surg Pak; 2014 Jun; 24(6):400-3. PubMed ID: 24953912
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Lox in triple-negative breast cancer.
Leo C; Cotic C; Pomp V; Fink D; Varga Z
Ann Diagn Pathol; 2018 Jun; 34():98-102. PubMed ID: 29661738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]